Patents Assigned to Universitat
  • Publication number: 20140154590
    Abstract: The invention relates to an electrolyte, comprising at least one lithium salt, a solvent, and at least one compound according to general formula (1). The invention further relates to lithium-based energy stores comprising such an electrolyte.
    Type: Application
    Filed: August 2, 2012
    Publication date: June 5, 2014
    Applicant: WESTFALISCHE WILHELMS UNIVERSITAT MUNSTER
    Inventors: Elisabeth Kramer, Rene Schmitz, Stefano Passerini, Martin Winter
  • Patent number: 8741570
    Abstract: The present invention pertains to a method and a device for the determination of thermo-optical properties, particularly the size or size distribution, of fluorescently labeled biomolecules or biomolecule complexes, particularly nucleic acids, in a reaction solution.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: June 3, 2014
    Assignee: Ludwig-Maximilians-Universitat Munchen
    Inventors: Stefan Duhr, Philipp Baaske
  • Patent number: 8743962
    Abstract: An embodiment of the invention relates to a method for providing a compressed video bitstream related to consecutive pictures of a video sequence, wherein the pictures are defined by pixels, said method comprising the steps of: (a) applying at least one higher-order motion model to a motion vector field and generating at least one higher-order motion parameter set for said motion vector field, wherein said motion vector field comprises a plurality of first motion vectors, each first motion vector being assigned to a pixel block and describing the local displacement of the pixel block from the preceding picture to the consecutive picture, and wherein each pixel block comprises a plurality of pixels; (b) calculating a second motion vector for each pixel block based on the higher-order motion parameter set; (c) calculating the deviation between the first motion vector and the second motion vector for each pixel block; and (d) generating a video bitstream comprising the higher-order motion parameter set, and f
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: June 3, 2014
    Assignee: Technische Universität Berlin
    Inventors: Andreas Krutz, Alexander Glantz, Thomas Sikora
  • Patent number: 8735136
    Abstract: Substantially pure biological culture of a strain of the species Pseudomonas graminis, deposited with number CBS136973 at the depositary institution “Centraalbureau voor Schimmelcultures” (CBS) in Utrecht, Netherlands. Use of the CBS136973 culture as an antagonist for the biocontrol of foodborne pathogenic bacteria in fruit intended for human consumption. Method for treating the fruit which comprises the step of applying a preparation that comprises a culture of a strain of the species Pseudomonas graminis, deposited with number CBS136973 at the depositary institution “Centraalbureau voor Schimmelcultures” (CBS) in Utrecht, Netherlands, to the fruit. The application thereof makes it possible to reduce the growth of pathogens during the shelf life of the product, especially when the cold chain is broken.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: May 27, 2014
    Assignees: Institut de Recerca I Tecnologia Agroalimentaries, Universitat de Lleida
    Inventors: Immaculada Vinas Almenar, Maria Isabel Abadias Sero, Josep Usall Rodie, Neus Teixido Espasa, Rosario Torres Sanchis
  • Publication number: 20140140949
    Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.
    Type: Application
    Filed: August 16, 2013
    Publication date: May 22, 2014
    Applicants: Christian-Albrechts-Universität Zu Kiel, Baker Medical Research Institute
    Inventors: Mark Anthony Febbraio, Stefan Rose-John
  • Publication number: 20140139845
    Abstract: The present invention relates to an optical coherence tomography system having an interferometer, in particular a Michelson interferometer, having a reference arm for variable adjustment of an optical reference path length and having a measuring arm in which an object to be scanned can be disposed and/or is disposed in a sample volume, wherein a focusing system which is configured for focusing divergently incident light beams on a common point situated in the sample volume is disposed in the measuring arm between the beam splitter of the interferometer and the sample volume.
    Type: Application
    Filed: January 27, 2014
    Publication date: May 22, 2014
    Applicants: Technische Universitat Dresden, Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung e.V.
    Inventors: Bjorn Fischer, Edmund Koch
  • Publication number: 20140141410
    Abstract: The invention provides for a method for the detection of FeLV infection in a patient, wherein a sample obtained from the patient is contacted in-vitro with a recombinant transmembrane p15E protein in a p15 (E) antibody binding step.
    Type: Application
    Filed: July 6, 2012
    Publication date: May 22, 2014
    Applicant: UNIVERSITAT ZURICH
    Inventors: Hans Lutz, Eva Bonzli, Regina Hofmann-Lehmann
  • Publication number: 20140134155
    Abstract: The invention relates to recombinant antibodies which bind to prostate-specific stem cell antigen (PSCA). The antibody of the invention comprises complementarity-determining regions (CDR) having the following amino acid sequences: CDR of the variable region of the light chain: CDR1 SEQ ID No. 1, CDR2 SEQ ID No. 2, CDR3 SEQ ID No. 3, and CDR of the variable region of the heavy chain: CDR1 SEQ ID No. 4, CDR2 SEQ ID No. 5, CDR3 SEQ ID No. 6. The invention also embraces the use of the antibodies of the invention as medicinal products, especially for the treatment of tumour diseases, or as a diagnostic agent. The antibodies are suitable for use in the areas of medicine, pharmacy and biomedical research.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 15, 2014
    Applicant: Technische Universität Dresden
    Inventor: Michael Bachmann
  • Publication number: 20140125332
    Abstract: A magnetostrictive layer system is suggested comprising at least one layer sequence comprising an anti-ferromagnetic, (AFM), layer and a magnetostrictive, ferromagnetic, FM, layer arranged directly thereon, wherein the layer sequence has an associated exchange bias, EB, field, the EB-induced degree of magnetization of the FM layer in the absence of an external magnetic field being within a range between 85% and 100%, and the angle ?opt, which is enclosed by the EB field direction and the magnetostriction direction, that has the maximum piezomagnetic coefficient in the absence of an external magnetic field, within a plane parallel to the AFM layer and the FM layer lies within a range between 10° and 80°.
    Type: Application
    Filed: June 20, 2012
    Publication date: May 8, 2014
    Applicant: CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL
    Inventors: Enno Lage, Dirk Meyners, Eckhard Quandt
  • Publication number: 20140127219
    Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLDN6, including tumor-related diseases such as ovarian cancer, lung cancer, gastric cancer, breast cancer, hepatic cancer, pancreatic cancer, skin cancer, malignant melanoma, head and neck cancer, sarcoma, bile duct cancer, cancer of the urinary bladder, kidney cancer, colon cancer, placental choriocarcinoma, cervical cancer, testicular cancer, and uterine cancer.
    Type: Application
    Filed: April 20, 2012
    Publication date: May 8, 2014
    Applicants: JOHANNES GUTENBERG-UNIVERSITÄT MAINZ, GANYMED PHARMACEUTICALS AG
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Stefan Wöll, Maria Kreuzberg, Bernd Hubner, Michael Erdeljan, Michael Weichel
  • Patent number: 8718803
    Abstract: A method for calculating measures of similarity between time signals, which includes: acquiring and comparing data (xi, yj) of time signals (X, Y); assigning a one or a zero to every two compared data (xi, yj), depending on the result of said comparison, creating a data set; determining time sequences with said ones and zeros of the data set, each one being formed by consecutive sub-sequences of ones, separated by discontinuities of zeros; selecting the highest result of accumulated results obtained for each sub-sequence, adding for each determined point i, j of value one said one to the accumulated result of maximum value, from among the accumulated results at a point i?1, j?1 of said sub-sequence, a point i?2, j?1 of a sub-sequence of a second time sequence, and a point i?1, j?2 of a sub-sequence of a third sequence.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: May 6, 2014
    Assignee: Universitat Pompeu Fabra
    Inventor: Joan Serra Julià
  • Patent number: 8715682
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Mazimillians-Universitat Wurzburg, a German University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Patent number: 8716030
    Abstract: Embodiments of the present invention provide for novel peptides of use for detection and/or inhibition of anti-?1-adrenergic receptor antibodies. Certain embodiments concern uses of cyclic and/or linear peptides. In other embodiments, the present invention relates to novel peptides of use in diagnostic and/or pharmaceutical compositions. Some embodiments concern diagnosing and/or treating cardiac conditions. Cardiac conditions of the instant invention can concern infectious heart disease, non-infectious heart disease, ischemic heart disease, non-ischemic heart disease, inflammatory heart disease, myocarditis, cardiac dilatation, idiopathic cardiomyopathy, idiopathic dilated cardiomyopathy, immune-cardiomyopathy, heart failure, and any cardiac arrhythmia condition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: May 6, 2014
    Assignee: Julius-Maximillians-Universitat Wurzburg, A Germany University
    Inventors: Roland Jahns, Valérie Jahns, Martin J. Lohse, Dieter Palm
  • Patent number: 8716485
    Abstract: The invention describes a novel process for synthesizing pyrazoles by means of oxidative conversion of enamines with suitable N-containing carboxylic acid derivatives.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: May 6, 2014
    Assignee: Westfälishe Wilhelms-Universität Münster
    Inventors: Julia Neumann, Mamta Suri, Frank Glorius
  • Publication number: 20140116892
    Abstract: Arrangements are described for evaluating characteristics of target molecules. A biochip is received which includes a substrate to which charged probe molecules are attached. The probe molecules have a marker to allow generating signals indicative of the distance of a portion of the probe molecule from the substrate. The signals are detected and means for an external electric field is generated to which the probe molecules are exposed. A control means acts to: (A) apply an external electric field causing the portion of the probe molecule to approach the substrate, and (B) apply an external electric field causing the portion of the probe molecule to move away from the substrate. The signal is recorded as a function of time during step (A) and/or step (B). Steps (A) and (B) are repeated for a predetermined number of times and the recorded signals are combined.
    Type: Application
    Filed: March 26, 2013
    Publication date: May 1, 2014
    Applicant: TECHNISCHE UNIVERSITÄT MÜNCHEN
    Inventor: TECHNISCHE UNIVERSITÄT MÜNCHEN
  • Publication number: 20140121264
    Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.
    Type: Application
    Filed: October 23, 2013
    Publication date: May 1, 2014
    Applicant: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURG
    Inventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
  • Publication number: 20140121171
    Abstract: miRNA-21 inhibitors and pharmaceutical compositions including an miRNA-21 inhibitor together with pharmaceutical excipients and carriers for use in the treatment of a muscular dystrophy and/or a muscular dystrophy-like myopathy. Particularly, the miRNA-21 inhibitors and pharmaceutical compositions including the same are for use in the regeneration of skeletal muscle in muscular dystrophy and/or a muscular dystrophy-like myopathy patients.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 1, 2014
    Applicants: INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS, UNIVERSITAT POMPEU FABRA
    Inventors: Purificación Muñoz-Cánoves, Marina Raya Chamorro, Eusebio Perdiguero Santamaría, Antonio Luis Serrano
  • Patent number: 8709377
    Abstract: The present invention relates to a process for reversible hydrogen storage, to a material for reversible hydrogen storage and to the use of the material for reversible hydrogen storage.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: April 29, 2014
    Assignee: Universitat Heidelberg
    Inventors: Hans-Jörg Himmel, Elisabeth Kaifer, Oxana Ciobanu, Pascal Roquette, Walter Siebert
  • Patent number: 8709437
    Abstract: The present invention pertains to the identification and initial characterization of CctA, a novel, secreted toxin of Clostridium chauvoei that represents the major cytotoxic activity of C. chauvoei. This toxin confers C. chauvoei its characteristic strong hemolytic activity towards erythrocytes of various species, since anti-CctA antibodies fully neutralize hemolysis by C. chauvoei on standard blood-agar medium or in cell-free supernatants of liquid cultures.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: April 29, 2014
    Assignees: Intervet International B.V., Universitat Bern
    Inventors: Keith Redhead, Joachim Frey, Edy M. Vilei, Andreas Walter Claudius Rohwer, Anders Johansson
  • Patent number: 8709399
    Abstract: The present invention relates to a new method for pest control and/or for preventing or treating pest infestation. Said method comprises the inoculation of plants, parts of plants or the surrounding of said plants with an effective amount of endophytic Beauveria bassiana strains. In a further aspect the present invention relates to the use of an isolated Beauveria bassiana strain having superior properties. Furthermore, biopesticides and compositions for pest control, in particular, for control of herbivorous insects and/or plant pathogens, are provided.
    Type: Grant
    Filed: March 24, 2011
    Date of Patent: April 29, 2014
    Assignee: Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts
    Inventors: Stefan Vidal, Tadele Tefera